key: cord-1008749-7ha0cxlf
authors: Stoyanov, Dr Alex; Thompson, Dr Graeme; Lee, Dr Monique; Katelaris, Professor Connie
title: Delayed hypersensitivity to the Comirnaty COVID-19 vaccine presenting with pneumonitis and rash
date: 2021-11-20
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2021.11.014
sha: 583ee0b3328bb8579afc5497e614fd5e9ed7524b
doc_id: 1008749
cord_uid: 7ha0cxlf

nan

Clinical trials have supported the efficacy of vaccines for the prevention of infection and widespread vaccination is now seen as a cornerstone in preventing mortality. 1 Post-approval surveillance has however demonstrated rare but significant vaccine associated complications, including thrombosis with thrombocytopenia syndrome following the adenovirus vector ChAdOX1-S and Janssen vaccines 2 and myocarditis with mRNA-based vaccines. 3 This has highlighted the importance of ongoing pharmacovigilance and prompt reporting of suspected vaccine associated adverse events. Here we present a case of inflammatory pneumonitis and fixed rash following a second dose of the BioNTech Comirnaty COVID-19 vaccine with delayed hypersensitivity seen on skin testing.

A 55-year-old female presented to hospital 6 days after the second dose of the Comirnaty COVID-19 vaccine with malaise, fever, cough and an abdominal rash. She had tolerated the first dose, three weeks prior, with brief pain at the injection site but no other signs of reactogenicity.

The patient initially tolerated the second vaccination but a large, fixed, confluent, erythematous, non-tender rash emerged over the right lower abdomen 48 hours after the dose.

Notably, there were no accompanying skin changes over the injection site. The rash remained in a fixed distribution thereafter, and did not improve with oral antimicrobial therapy. Four days following vaccination, she then developed a persistent non-productive cough accompanied by progressive dyspnoea, rigors, nausea and anorexia which eventually prompted her presentation to hospital.

On presentation, the patient was hypoxic with oxygen saturations of 91% on room air and febrile to 39.6 degrees Celsius. Blood investigations revealed lymphopenia with a lymphocyte count of 0.4x10 9 /L and markedly elevated inflammatory markers with C-reactive protein of 512mg/L but no other significant organ dysfunction. Multifocal bilateral lung infiltrates were seen on chest X-ray with confluent changes in the right lower lobe.

The patient was commenced on intravenous ceftriaxone and azithromycin for presumed community acquired pneumonia but remained persistently febrile and hypoxic. Given the lack of response to broad spectrum antibiotics, a non-infective inflammatory pneumonitis related to vaccination was considered, particularly in light of the abdominal rash.

On the third day of admission, prednisone 25mg daily was added to ongoing antibiotics; within 24 hours there was resolution of the fevers, improvement in the patient's symptoms and downtrend in inflammatory markers. Topical 0.1% methylprednisone ointment was applied to the abdominal rash, which resolved following several days. Skin histopathology, taken on the day of admission, subsequently demonstrated mixed dermatitis with perivascular eosinophils and negative direct immunofluorescence, consistent with a drug reaction.

The patient was discharged on the sixth day of admission and completed a further week of oral antibiotics and tapering prednisone with complete resolution of symptoms. Due to the atypical cells on bronchoscopy, a positron emission tomography (PET) scan was performed one month later which showed mild glucose avidity in the right middle lobe and lingula consistent with resolving inflammation but no other pulmonary lesions. Skin prick and intradermal testing to the Comirnaty COVID-19 vaccine showed no immediate reaction but a large 38x45mm intradermal reaction to the 1:10 dilution of the vaccine was seen at 48 hours, consistent with delayed hypersensitivity. This case demonstrates a previously undescribed delayed hypersensitivity to the Comirnaty COVID-19 vaccine presenting with pneumonitis and a fixed rash. Whilst other causes for the patient's presentation were considered, the lack of microbiological findings on bronchial fluid and minimal response to antibiotic therapy supported an inflammatory rather than infective cause, and no evidence of malignancy was subsequently found. Although positive delayed skin testing reactions can indicate a normal cellular immune response to mRNA COVID-19 vaccines 4 , the profound intradermal reaction seen in our patient, along with morphological similarities to the original rash and skin biopsy findings supported vaccine related hypersensitivity.

Vaccine related pneumonitis has been reported following influenza vaccination and is thought to occur due to immune-mediated lung injury with demonstrated in vitro proliferation of lymphocytes. 5 Meanwhile, respiratory complications following other vaccines including COVID-19 vaccines are not well described. To date, there has been one report of pulmonary nodules following mRNA-1273 vaccination but these were not glucose avid on PET and hence likely benign 6 , whilst a case of acute respiratory distress syndrome has been recently reported. 7 In contrast, delayed cutaneous local reactions at injection sites, coined "COVID arm", occur in up to 1% of recipients of mRNA COVID-19 vaccines. 8 Distant and generalised cutaneous reactions including urticaria and morbilliform rashes have also been described more recently.

These typically occur up to one week after first dose or 2 to 4 days following the second dose, consistent with our patient's rash. 9 Whilst vaccine specific lymphocyte responses could not be performed in our patient, the intradermal testing and histopathological features on skin biopsy support a possible T cell mediated mechanism. Unlike the majority of delayed localised cutaneous reactions, our patient's presentation occurred after the second dose of the vaccine but this phenomenon is well described in delayed drug hypersensitivity and it is established that cellular responses are greater following the second vaccine dose. 10 The mechanism by which reactive lymphocytes may be generated remains unclear but immediate and delayed skin testing to polyethylene glycol (PEG 3350), one of the excipients in the Comirnaty vaccine, was negative at several concentrations. This suggests that the process was possibly driven by other components, including the lipid-based nanoparticle carrier. We therefore recommended that our patient avoid all mRNA COVID-19 vaccines, but can receive non-mRNA based vaccines if booster doses are required.

In summary, we describe a unique presentation of delayed hypersensitivity to the Comirnaty COVID-19 vaccine. This case adds to the growing evidence for rare delayed reactions to COVID-19 vaccines and highlights the importance of ongoing pharmacovigilance as the vaccine rollout continues. 

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 vaccination

Myocarditis with COVID-19 mRNA vaccines

Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing

Influenza vaccine-induced interstitial lung disease

)F-fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine

A patient presenting with ARDS after COVID-19 vaccination: A COVID-19 case report

Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases

COVID-19 vaccine BNT162b1 elicits human antibody and Th1 T cell responses